Ensign Group Expands Foothold in Three U.S. States With Facility Buyouts

The Ensign Group, Inc. ENSG recently acquired operations of four skilled nursing facilities effective Dec. 1, 2025. These include The Rehabilitation Center at Sandalwood, Edgewater Health and Rehabilitation, Willow Point Rehabilitation and Nursing Center and Santa Rosa Care Center. The first two facilities are located in Colorado and are equipped with 103 and 69 beds, respectively. The third facility comprises 45 beds and is situated in Kansas, while the fourth one is located in Arizona and equipped with 144 beds. 

These facilities are operated under long-term, triple net leases with third-party landlords, while the Kansas facility’s real estate was purchased by Standard Bearer Healthcare REIT, Ensign’s captive real estate arm.

By collaborating closely with dedicated caregiver teams at its newly acquired facilities, ENSG will deepen its understanding of the unique needs of local communities, enabling it to deliver enhanced, patient-centered care to residents and their families.

The transactions have taken the count of Ensign Group’s portfolio to a total of 373 healthcare operations, including 47 senior living facilities, spread across 17 states. Additionally, Ensign Group’s subsidiaries—such as Standard Bearer Healthcare REIT—presently own 156 real estate assets.

Benefits Reaped by Ensign Group Out of Such Expansion Initiatives

Apart from a growing healthcare portfolio, the recent facility buyouts are expected to strengthen ENSG’s presence across Colorado, Arizona and Kansas. 

The year 2025 so far has been quite active for the company on the acquisition front. Some other states in which Ensign Group has undertaken similar moves so far in 2025 remain those of Utah, Alabama, Wisconsin, Iowa, to name a few. This consistent pace of strategic growth has greatly bolstered its expansion into various communities across the United States, reinforcing its national footprint. These efforts have played a key role in bridging care gaps and delivering essential support to underserved populations in need of quality healthcare services. 

The addition of more skilled nursing facilities, such as those in the recent acquisition, enables the healthcare provider to reach a wider patient base, potentially driving robust revenue growth within its Skilled Services segment. This segment has traditionally been a key revenue driver for ENSG, contributing 96% of total revenues during the first nine months of 2025. Furthermore, the acquisition of the Kansas-based facility is expected to enhance rental income generated through Ensign Group’s real estate arm, Standard Bearer.

ENSG’s Share Price Performance & Zacks Rank

Shares of Ensign Group have gained 24.4% in the past year compared with the industry’s 22.7% growth. ENSG currently carries a Zacks Rank #2 (Buy).

Other Stocks to Consider

Some other top-ranked stocks in the Medical space are Collegium Pharmaceutical, Inc. COLL, ANI Pharmaceuticals, Inc. ANIP and Intuitive Surgical, Inc. ISRG, each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Collegium Pharmaceutical’s earnings surpassed estimates in each of the last four quarters, the average surprise being 10.63%. The Zacks Consensus Estimate for COLL’s 2025 earnings indicates a rise of 17.1% from the 2024 figure. The consensus mark for revenues implies an improvement of 24.2% from the 2024 figure. The consensus mark for COLL’s 2025 earnings has moved 6.6% north in the past 30 days.

The bottom line of ANI Pharmaceuticals outpaced estimates in each of the trailing four quarters, the average surprise being 21.24%. The Zacks Consensus Estimate for ANIP’s 2025 earnings indicates a rise of 45% from the 2024 figure. The consensus mark for revenues implies an improvement of 41.6% from the 2024 figure. The consensus mark for ANIP’s 2025 earnings has moved 3.4% north in the past 30 days.

Intuitive Surgical’s earnings surpassed estimates in each of the last four quarters, the average surprise being 16.34%. The Zacks Consensus Estimate for ISRG’s 2025 earnings indicates a rise of 17.3% from the 2024 figure. The consensus mark for revenues implies an improvement of 18.7% from the 2024 figure. The consensus mark for ISRG’s 2025 earnings has moved 5.5% north in the past 60 days.

Shares of Collegium Pharmaceutical, ANI Pharmaceuticals and Intuitive Surgical have gained 53.7%, 44.7% and 2.7%, respectively, in the past year. 

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research